Genmab's Epcoritamab Shows Strong Subgroup Efficacy in Relapsed Follicular Lymphoma
Event summary
- Genmab presented EPCORE® FL-1 subgroup data at the 2026 EHA Congress, showing consistent efficacy and safety of epcoritamab + R2 across relapsed/refractory follicular lymphoma patients.
- The Phase 3 trial randomized 481 patients, with 243 receiving epcoritamab + R2 and 238 receiving R2 alone.
- Progression-free survival (PFS) benefits favored epcoritamab + R2 across FLIPI scores, POD24 status, and patient fitness categories.
- Overall response rates (ORR) and complete response rates (CRR) were significantly higher with the combination therapy compared to R2 alone.
- The safety profile of epcoritamab + R2 was manageable across all patient subgroups.
The big picture
Genmab's positive subgroup data for epcoritamab in combination with rituximab and lenalidomide reinforces its potential to transform the treatment paradigm for relapsed/refractory follicular lymphoma. The consistent efficacy and manageable safety profile across diverse patient subgroups position the therapy as a strong contender in the competitive landscape of hematologic malignancies. The collaboration with AbbVie further amplifies the commercial potential, with shared responsibilities in key markets.
What we're watching
- Regulatory Approvals
- The pace at which Genmab and AbbVie secure additional regulatory approvals for epcoritamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.
- Commercialization Strategy
- How Genmab and AbbVie will leverage these results to expand the commercial reach of epcoritamab, particularly in the U.S. and Japan.
- Clinical Pipeline
- The progress of ongoing Phase 3 trials evaluating epcoritamab in combination with other therapies across various hematologic malignancies.
Related topics